C 21 H 18 FN 3 O 3 S, monoclinic, P 21 (no. 4), a = 11.6665(3) Å,
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Experimental details
Carbon-bound H-atoms were positioned geometrically (C-H = 0.93-0.98 Å) and were included in the re nement in the riding model approximation, with U iso (H) = 1.2 Ueq(C). The H atoms bonded to N3 and the hydroxyl H atom bonded to O1 were located in a di erence Fourier map and treated as riding atoms with U iso (H) = 1.2 Ueq(N) for the NH 2 group and U iso (H) = 1.5 Ueq(O) for the hydroxyl group. The absolute structure was determined [22] from 1726 Friedel pairs. The Flack parameter re nes to a value of 0.04(2) [19] .
Discussion
Pyrazolines are prominent nitrogen containing ve membered heterocyclic compounds possessing broad spectrum of bioactivities such as antimicrobial [2, 3] , antiin ammatory [4] , antitubercular and anelgesic [5] , LDL-oxidation inhibitor [6] , antidepresant [7] activities. Medicinally important pyrazoline derivatives are 1,3,5-trisubstituted pyrazolines. There are several studies reporting their bioactivities such as antimicrobial, antiin ammatory [1, 8] , blood glucose lowering activity or antidiabetic [8] , selectivite COX-2 inhibition [9] , dipeptidyl peptidase-IV (DP-IV) inhibition [10] activities.
Coumarin bearing 2-pyrazoline hybrids endowed with phenylsulfonyl moiety presented antitumor activity [11] . Antiin ammatory and anticancer activities of 2-pyrazoline bearing benzene sulfonamides were reported [12, 13] .
In the title structure (Fig.) . The pyrazole ring (N1/N2/C7-C9) exhibits an envelope conformation [the puckering parameters [14] are Q(2) = 0.150(3) Å and φ(2) = 76.5(9)°], with the methine C9 atom being the ap atom. The central pyrole ring makes dihedral angles of 8.33 (12) , 87.06(13) and 7.27(12)°, respectively, with the hydroxy-and uoro-benzene rings (C1-C6 and C10-C15) and the benzenesulfonamide ring (C16-C21).
The bond lengths and bond angles in the title compound are normal and are almost similar to those reported earlier for the related structures [15, 16] .
In the benzenesulfonamide group, the sulfonamide oxygen atom O3 is involved in an intramolecular C-H· · · O hydrogen bond with C18, forming a S(5) ring [17] . The crystal structure is stabilized by intermolecular N-H· · · O, O-H· · · O and C-H· · · O hydrogen bonds and C-H· · · π interactions, forming a three dimensional network.
